By positively regulating oncogenes such as VEGF and B‐cell lymphoma 2 (BCL‐2) (Karadedou et al., 2012; Liu et al., 2017b), FOXM1 impacts tumor initiation, angiogenesis, progression, drug resistance, and metastasis in prostate cancer, hepatocellular carcinoma, pancreatic cancer, colon cancer, breast cancer, and glioblastoma (Bella et al., 2014). This evidence concerns the gene VEGFA and neoplasm.